Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.

Switching from finasteride to a generic dutasteride led to unexpectedly high DHT levels, prompting a switch to a reputed brand and consideration of softgel capsules for better absorption. The user plans to retest DHT levels and may return to finasteride if issues persist.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

People discussed using finasteride, minoxidil, and dutasteride for hair loss, with mixed results and side effects. Some had positive outcomes, while others experienced issues like libido changes and chose alternatives like hair systems.

A user shared their hormone levels to gauge if they can use finasteride for hair loss without issues. Their hormone levels are mostly within the reference ranges.

The conversation discusses using TH16, a topical melatonin with resveratrol, and stemoxydine for hair maintenance, avoiding finasteride and minoxidil due to side effects. The user is considering a low-dose topical finasteride despite sensitivity.

PP405 shows promise in hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil, with significant results in just four weeks. The treatment is still in early stages, with further trials needed to determine its long-term effectiveness and optimal dosage.

A user is considering adding PRP and mesotherapy to their hair loss treatment and is deciding between two options: Promoitalia, which contains Phosphatidic acid, Riboflavin, and Superoxide dismutase, and the more expensive Melsmon, a human placenta derivative. They seek advice on which option to choose based on effectiveness and scientific backing.

Despite using Dutasteride, RU58841, and Minoxidil, hair loss continues due to low testosterone levels from taking 15mg of testosterone weekly, which may not produce enough estrogen. Increasing testosterone dosage and stabilizing hormone levels might help address the issue.

The user has been using oral minoxidil (5mg) and oral finasteride (1.25mg) for 9 months and is considering switching to dutasteride due to concerns about hair shedding. They report no side effects from the current treatment.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

The conversation discusses the uncertainty of the legitimacy of minoxidil products in the EU market and mentions baricitinib as an approved, but expensive alternative. A method to test for real minoxidil involves mixing it with bleach to see if it turns orange or brown.

A user ordered a 10% minoxidil product with caffeine and retinol from Hair Medics UK and is seeking reviews. They are interested in higher percentage minoxidil treatments for hair loss.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

Finasteride can affect hormone levels within two weeks, and a break of several weeks is recommended for baseline results. Monitoring E2 and testosterone is suggested to assess the risk of gynecomastia.

The user has been on finasteride for 4.5 years and minoxidil for 10 years, maintaining hair but not regrowing much on the crown and temples. They are considering using a dermastamp more frequently and possibly trying RU58841, but are hesitant about dutasteride due to concerns about side effects and DHT suppression.

A 19-year-old concerned about long-term effects of 5AR inhibitors on physical appearance. They have used finasteride and plan to try dutasteride or RU58841; responses suggest improved skin, hair, and confidence.

A user is combining RU58841 with a topical formula containing finasteride, dutasteride, minoxidil, triamcinolone, caffeine, and other ingredients. They have just started using it and report no side effects so far.

Finasteride is favored for hair loss due to FDA approval, accessibility, and manageable side effects. Dutasteride, though more effective in reducing DHT, is used off-label and may have more side effects.

Mixing topical finasteride with essengen f and stemoxydine creates 0.25mg dose in 2ml. Minoxidil max suggests mixing 8.5ml essengen f with 60ml solvent for 0.25mg dose in 1ml.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The user experienced side effects from finasteride and is considering switching to dutasteride, while also using pyrilutamide to protect hair follicles. They are seeking advice on whether to add RU58841 to their regimen.

A user experienced worsening hair recession after adding 0.5 mg daily dutasteride to their regimen of topical minoxidil and finasteride, despite no initial shedding. They plan to continue monitoring the situation, as others suggest it may be too early to see results and recommend blood tests to check DHT levels.